Pensionfund Sabic Makes New Investment in Cencora, Inc. $COR

Pensionfund Sabic bought a new stake in Cencora, Inc. (NYSE:COR) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 4,800 shares of the company’s stock, valued at approximately $1,621,000.

A number of other institutional investors have also recently made changes to their positions in the company. IAG Wealth Partners LLC purchased a new stake in shares of Cencora during the third quarter worth approximately $30,000. Vermillion & White Wealth Management Group LLC lifted its holdings in Cencora by 69.4% in the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock valued at $31,000 after purchasing an additional 43 shares in the last quarter. Cloud Capital Management LLC acquired a new stake in Cencora during the 3rd quarter worth $31,000. Caitlin John LLC acquired a new stake in Cencora during the 3rd quarter worth $31,000. Finally, Westside Investment Management Inc. grew its holdings in shares of Cencora by 200.0% during the third quarter. Westside Investment Management Inc. now owns 105 shares of the company’s stock worth $33,000 after buying an additional 70 shares in the last quarter. 97.52% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Cencora news, CEO Robert P. Mauch sold 5,096 shares of Cencora stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total transaction of $1,807,704.08. Following the completion of the sale, the chief executive officer directly owned 66,726 shares in the company, valued at $23,669,713.98. This trade represents a 7.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.38% of the stock is currently owned by company insiders.

Cencora Price Performance

NYSE:COR opened at $327.12 on Wednesday. Cencora, Inc. has a 52 week low of $265.59 and a 52 week high of $377.54. The company has a quick ratio of 0.51, a current ratio of 0.92 and a debt-to-equity ratio of 3.62. The company has a market capitalization of $63.63 billion, a P/E ratio of 39.32, a P/E/G ratio of 1.49 and a beta of 0.68. The stock’s fifty day moving average is $354.13 and its two-hundred day moving average is $340.68.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share for the quarter, topping analysts’ consensus estimates of $4.04 by $0.04. The business had revenue of $85.93 billion during the quarter, compared to analysts’ expectations of $86.12 billion. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The company’s revenue was up 5.5% compared to the same quarter last year. During the same period in the prior year, the business posted $3.73 EPS. Equities analysts expect that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, March 2nd. Shareholders of record on Friday, February 13th were paid a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend was Friday, February 13th. Cencora’s dividend payout ratio (DPR) is 28.85%.

Cencora News Roundup

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: The acquisition expands Cencora’s Retina Consultants of America platform and strengthens its footprint in the fast-growing eye care market, adding scale and potential cross-selling opportunities for pharma and services. Cencora to buy EyeSouth’s retina business for $1.1 billion
• Positive Sentiment: Analyst and trade coverage frames the deal as a clear add-on to RCA that builds scale in a specialty with high procedure volumes and recurring treatment needs, which could support revenue and margin improvement over time. COR to Expand Retina Consultants of America With $1.1B EyeSouth Deal
• Neutral Sentiment: The transaction is widely reported across outlets (Reuters, Seeking Alpha, Fierce Healthcare), which helps transparency and may accelerate investor re-pricing; details on financing and expected contribution to guidance remain limited. Cencora to buy retina business of EyeSouth Partners for $1.1 billion
• Neutral Sentiment: COR is included in actively managed ETF baskets highlighted by MarketBeat, which can bring incremental demand from fund flows rather than direct company fundamentals. That placement may amplify moves in COR shares as funds trade. Active ETFs Surge Past Passive, and These Are in the Lead (COR)
• Negative Sentiment: Potential near-term negatives include transaction financing, integration costs and execution risk; Cencora already carries a relatively high debt-to-equity ratio, so investors should watch how the deal is funded and whether it materially affects leverage. Conshohocken’s Cencora Prepares for Leadership Change This Summer

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on COR shares. Weiss Ratings upgraded shares of Cencora from a “hold (c+)” rating to a “buy (b)” rating in a research report on Thursday, February 5th. JPMorgan Chase & Co. upped their price objective on shares of Cencora from $417.00 to $419.00 and gave the company an “overweight” rating in a research note on Tuesday, February 10th. Wells Fargo & Company increased their price objective on shares of Cencora from $405.00 to $429.00 and gave the company an “overweight” rating in a report on Tuesday, February 10th. Jefferies Financial Group raised shares of Cencora from an “underperform” rating to a “buy” rating in a research note on Thursday, January 22nd. Finally, Wall Street Zen lowered Cencora from a “buy” rating to a “hold” rating in a research report on Friday, November 28th. Twelve equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $403.17.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.